NO20045019L - Farmasoytisk preparat - Google Patents

Farmasoytisk preparat

Info

Publication number
NO20045019L
NO20045019L NO20045019A NO20045019A NO20045019L NO 20045019 L NO20045019 L NO 20045019L NO 20045019 A NO20045019 A NO 20045019A NO 20045019 A NO20045019 A NO 20045019A NO 20045019 L NO20045019 L NO 20045019L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparation
preparation
patient
macrocyclic
cyclic enhancer
Prior art date
Application number
NO20045019A
Other languages
English (en)
Other versions
NO335864B1 (no
Inventor
Robert J Gyurik
Original Assignee
Bentley Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29251138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20045019(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bentley Pharmaceuticals Inc filed Critical Bentley Pharmaceuticals Inc
Publication of NO20045019L publication Critical patent/NO20045019L/no
Publication of NO335864B1 publication Critical patent/NO335864B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Farmasøytisk preparat omfattende: (A) androgen, (B) en syklisk forsterker av typen anvendt i preparatene og fremgangsmåtene ifølge US 5 023 252 (Hsieh), og (C) et fortykningsmiddel, hvor den sykliske forsterker kan være en makrosyklisk ester eller et makrosyklisk keton. Preparatet anvendes til å behandle for eksempel mannlig hypogonadisme ved at pasienten far påført preparatet på en membran på pasienten. Det beskrives også en fremgangsmåte for fremstilling av preparatet.
NO20045019A 2002-04-19 2004-11-18 Farmasøytisk preparat omfattende testosteron eller dihydrotestosteron og oksasykloheksadekan-2-on; anvendelse derav til fremstilling av et medikament og fremgangsmåte for fremstilling av preparatet. NO335864B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37410302P 2002-04-19 2002-04-19
PCT/US2003/012235 WO2003088974A1 (en) 2002-04-19 2003-04-21 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
NO20045019L true NO20045019L (no) 2005-01-14
NO335864B1 NO335864B1 (no) 2015-03-09

Family

ID=29251138

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045019A NO335864B1 (no) 2002-04-19 2004-11-18 Farmasøytisk preparat omfattende testosteron eller dihydrotestosteron og oksasykloheksadekan-2-on; anvendelse derav til fremstilling av et medikament og fremgangsmåte for fremstilling av preparatet.

Country Status (30)

Country Link
US (21) US7320968B2 (no)
EP (2) EP1741433B1 (no)
JP (1) JP2005519985A (no)
KR (2) KR100977896B1 (no)
CN (2) CN102357098B (no)
AR (2) AR039644A1 (no)
AT (1) ATE371456T1 (no)
AU (1) AU2003228612B2 (no)
BR (1) BR0309390A (no)
CA (1) CA2470200C (no)
CY (1) CY1109005T1 (no)
DE (1) DE60315939T2 (no)
DK (1) DK1425019T3 (no)
EA (1) EA009839B1 (no)
EG (1) EG24882A (no)
ES (2) ES2292964T3 (no)
HK (3) HK1082682A1 (no)
IL (1) IL164547A (no)
IS (2) IS2667B (no)
LT (1) LT5235B (no)
LV (1) LV13303B (no)
MX (1) MXPA04010311A (no)
MY (1) MY139721A (no)
NO (1) NO335864B1 (no)
NZ (1) NZ535970A (no)
PL (1) PL213976B1 (no)
SA (1) SA03240158B1 (no)
TW (1) TWI362932B (no)
WO (1) WO2003088974A1 (no)
ZA (1) ZA200408422B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
JP2008512425A (ja) * 2004-09-09 2008-04-24 ラボラトワール ブザン アンテルナスィヨナル 透過促進剤としてのプロピレングリコールを含むテストステロンゲル
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
PT1937276E (pt) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Gel de testosterona melhorado e método para a sua utilização
BRPI0908701A2 (pt) * 2008-05-09 2015-07-21 Tolmar Inc Composição, método para o tratamento de uma doença ou distúrbio de pelo ou mucosa, método para o tratamento de acne, método de extermínio ou inibição do crescimento de bactérias, protozoários ou fungos e uso de proguanil
CN102056593A (zh) * 2008-06-05 2011-05-11 Cpex药品公司 胰岛素鼻用制剂
US20110097363A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically Effective Preparations of Insulin
EP2640398A4 (en) 2010-11-18 2014-05-14 White Mountain Pharma Inc METHODS FOR TREATING CHRONIC OR REFRACTORY PAIN AND / OR INCREASING PAIN THRESHOLD IN A SUBJECT, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
KR102088038B1 (ko) * 2011-05-15 2020-03-13 에이세러스 바이오파마 인크. 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
US10568905B2 (en) * 2012-02-14 2020-02-25 Metabolic Therapy Inc. Pharmaceutical composition and method for treating retinal neurodegeneration
US9950125B2 (en) 2012-04-06 2018-04-24 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
IN2015KN00677A (no) 2012-09-20 2015-07-17 Gkn Armstrong Wheels Inc
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
WO2019089942A1 (en) * 2017-11-02 2019-05-09 Rick Coulon Formulations for use in the transdermal delivery of proteasome inhibitors
CN112666197B (zh) * 2020-11-29 2022-11-04 山东大学 一种用于tbm的岩渣石英含量测试系统及方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991203A (en) 1975-06-19 1976-11-09 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
BE843140A (fr) 1975-06-19 1976-10-18 Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US3989815A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Novel N-bis-azacyclopentan-2-onyl alkanes
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4424210A (en) 1980-04-04 1984-01-03 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4415563A (en) 1980-04-04 1983-11-15 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclononan-2-ones
US4423040A (en) 1980-04-04 1983-12-27 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclohexan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5270346A (en) 1986-01-31 1993-12-14 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4992422A (en) 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4879275A (en) 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US5019395A (en) 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
DE19619045C1 (de) 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
DE29824679U1 (de) 1997-01-30 2002-03-28 Novartis Ag, Basel Pharmazeutische Zusammensetzungen
DE29704393U1 (de) 1997-03-11 1997-07-17 Aesculap Ag, 78532 Tuttlingen Vorrichtung zur präoperativen Bestimmung der Positionsdaten von Endoprothesenteilen
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
DK1510213T3 (da) * 1997-11-10 2009-03-23 Strakan Int Ltd Penetrationsforbedrende og irritationsreducerende systemer omfattende testosteron
US6980952B1 (en) * 1998-08-15 2005-12-27 Texas Instruments Incorporated Source normalization training for HMM modeling of speech
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
FR2801507B1 (fr) * 1999-11-30 2003-06-27 Pf Medicament Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations
HUP0201450A3 (en) * 1999-12-08 2003-02-28 Pharmacia Corp Chicago Solid-state form of celecoxib having enhanced bioavailability, pharmaceutical compositions containing it and their preparation
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
KR100856523B1 (ko) * 2000-08-03 2008-09-04 안타레스 파르마 아이피엘 에이쥐 충분한 치료효과를 보장하는 활성 화합물의 경피 및/또는경점막 투여용 신규 조성물
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
ES2423899T3 (es) * 2000-08-30 2013-09-25 Unimed Pharmaceuticals, Llc Método para aumentar las concentraciones de testosterona y esteroides relacionados en las mujeres
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
PT1315502E (pt) 2000-08-30 2010-05-06 Unimed Pharmaceuticals Llc Método para tratar a disfunção eréctil e para aumentar a líbido em homens
WO2002055020A2 (en) 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
CA2432534C (en) * 2000-12-22 2009-09-22 Dr. August Wolff Gmbh & C0. Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism
CA2446060A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US7169107B2 (en) * 2002-01-25 2007-01-30 Karen Jersey-Willuhn Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system
HU230920B1 (hu) 2002-03-15 2019-03-28 Besins Healthcare Luxembourg Sarl Depresszió kezelésére szolgáló androgén gyógyászati készítmények
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259784A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Compositions and methods for treatment of muscle pain and muscle wasting

Also Published As

Publication number Publication date
US7608606B2 (en) 2009-10-27
US20160129016A1 (en) 2016-05-12
LT5235B (lt) 2005-06-27
TWI362932B (en) 2012-05-01
US20090192131A1 (en) 2009-07-30
ATE371456T1 (de) 2007-09-15
KR100952786B1 (ko) 2010-04-14
HK1098386A1 (en) 2007-07-20
US8178518B2 (en) 2012-05-15
US7608605B2 (en) 2009-10-27
AR039644A1 (es) 2005-03-02
CN102357098B (zh) 2014-12-17
AR087484A2 (es) 2014-03-26
DK1425019T3 (da) 2008-02-04
IS2667B (is) 2010-08-15
EP1425019B1 (en) 2007-08-29
EA200401410A1 (ru) 2005-04-28
TW200408397A (en) 2004-06-01
US20210308145A1 (en) 2021-10-07
US20090192132A1 (en) 2009-07-30
HK1082682A1 (en) 2006-06-16
ES2399900T3 (es) 2013-04-04
LT2004101A (en) 2005-04-25
US20100081640A1 (en) 2010-04-01
US20150283153A1 (en) 2015-10-08
US20090118250A1 (en) 2009-05-07
KR20090079266A (ko) 2009-07-21
CN102357098A (zh) 2012-02-22
EP1425019A1 (en) 2004-06-09
CN1662243A (zh) 2005-08-31
DE60315939D1 (de) 2007-10-11
US7608610B2 (en) 2009-10-27
NZ535970A (en) 2006-12-22
US20090118251A1 (en) 2009-05-07
PL372083A1 (en) 2005-07-11
KR20050011753A (ko) 2005-01-29
EG24882A (en) 2010-12-01
IL164547A0 (en) 2005-12-18
US20130059828A1 (en) 2013-03-07
EP1741433B1 (en) 2012-11-07
HK1167332A1 (en) 2012-11-30
MY139721A (en) 2009-10-30
KR100977896B1 (ko) 2010-08-24
CA2470200C (en) 2005-07-26
US20050192260A1 (en) 2005-09-01
EP1741433A1 (en) 2007-01-10
US20130281416A1 (en) 2013-10-24
US20080275013A1 (en) 2008-11-06
AU2003228612A1 (en) 2003-11-03
JP2005519985A (ja) 2005-07-07
IS7535A (is) 2004-11-17
US7608609B2 (en) 2009-10-27
US20210308146A1 (en) 2021-10-07
US8063029B2 (en) 2011-11-22
IS2946B (is) 2016-05-15
PL213976B1 (pl) 2013-05-31
EP1425019A4 (en) 2004-11-17
EA009839B1 (ru) 2008-04-28
US20080108590A1 (en) 2008-05-08
US20080103120A1 (en) 2008-05-01
US20140343025A1 (en) 2014-11-20
US7608607B2 (en) 2009-10-27
SA03240158B1 (ar) 2007-02-17
IL164547A (en) 2011-01-31
US20080275012A1 (en) 2008-11-06
CA2470200A1 (en) 2003-10-30
CN1662243B (zh) 2011-10-26
CY1109005T1 (el) 2014-07-02
WO2003088974A1 (en) 2003-10-30
ZA200408422B (en) 2006-06-28
US20090124589A1 (en) 2009-05-14
US20090131387A1 (en) 2009-05-21
LV13303B (en) 2006-08-20
MXPA04010311A (es) 2005-02-03
IS8870A (is) 2010-01-06
NO335864B1 (no) 2015-03-09
DE60315939T2 (de) 2008-05-21
US7935690B2 (en) 2011-05-03
US20090118252A1 (en) 2009-05-07
US7320968B2 (en) 2008-01-22
US20090124590A1 (en) 2009-05-14
BR0309390A (pt) 2005-02-09
ES2292964T3 (es) 2008-03-16
AU2003228612B2 (en) 2006-05-04
US7608608B2 (en) 2009-10-27

Similar Documents

Publication Publication Date Title
NO20045019L (no) Farmasoytisk preparat
WO2004024300A8 (en) Ultrafiltration membrane, device, bioartificial organ and methods
HUP0302060A2 (hu) Eljárás készítmények elżállítására
NO20030961D0 (no) Farmasöytisk preparat og metode for behandling av hypogonadisme
GB2355932A (en) A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
AU2021379265A1 (en) Eutectic compositions, methods and uses thereof
HUP0302099A2 (hu) Az azithromicin monohidrátja, eljárás az előállítására és a monohidrátot tartalmazó gyógyszerkészítmény
ATE312596T1 (de) Verfahren zur herstellung wasserdispergierbarer trockenpulver von in wasser schwer l slichen verbindungen
WO2003045326A3 (en) Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
DE602005018172D1 (de) Medizinische lösung; verfahren zur herstellung dieser lösung und ihre verwendung
JP2006124376A (ja) 発毛及び育毛剤
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
ATE179893T1 (de) Extrakt aus blüten von salvia officinalis, verfahren zu dessen herstellung und dessen verwendung
JO2545B1 (en) Pharmaceutical compound
JP7046304B2 (ja) ５α－レダクターゼ阻害剤の製造方法、及び脱毛症の予防治療用又は育毛促進用組成物の製造方法
AU4622800A (en) A stabilized isothiazolone composition and a method of stabilization of isothiazolone
DE50103561D1 (de) Verfahren zur herstellung von phyllanthusextrakten
WO2006042389B1 (en) Hydroalcoholic extract of erythrina mulungu, pharmaceutical compositions and processes for producing these substances
DE50105303D1 (de) Verfahren zur herstellung eines kosmetisch verwendbaren extraktes aus meeresschlick
TW202202163A (zh) 用以預防紫外線傷害的速溶組合物
DE60202602D1 (de) Mercaptoacetylamid-derivate, prozess zur herstellung sowie deren verwendung
CY1114137T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ανδρογονο
CN111000866A (zh) 一种聚维酮过氧化氢络合物的制备方法
TAKAHASHI et al. Soiling and soil removal from cotton fabric after DP finishing with polycarboxylic acid.
ATE381598T1 (de) Abbeizmittelzusammensetzung und verwendungen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees